BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luijten RK, Fritsch-stork RD, Bijlsma JW, Derksen RH. The use of glucocorticoids in Systemic Lupus Erythematosus. After 60years still more an art than science. Autoimmunity Reviews 2013;12:617-28. [DOI: 10.1016/j.autrev.2012.12.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Rua-Figueroa Fernández de Larrinoa Í, Lozano MJC, Fernández-Cid CM, Cobo T, Salman Monte TC, Freire González M, Hidalgo Bermejo FJ, Román Gutiérrez CS, Cortés-Hernández J. Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment. Expert Opin Biol Ther 2022;:1-9. [PMID: 35815355 DOI: 10.1080/14712598.2022.2096406] [Reference Citation Analysis]
2 Bertsias G. Recommendations for Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America 2022. [DOI: 10.1016/j.rdc.2022.05.001] [Reference Citation Analysis]
3 Mormile I, Punziano A, Riolo CA, Granata F, Williams M, de Paulis A, Spadaro G, Rossi FW. Common Variable Immunodeficiency and Autoimmune Diseases: A Retrospective Study of 95 Adult Patients in a Single Tertiary Care Center. Front Immunol 2021;12:652487. [PMID: 34290696 DOI: 10.3389/fimmu.2021.652487] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Oliveira M, Palacios-Fernandez S, Cervera R, Espinosa G. Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. Rheumatology (Oxford) 2020;59:3690-9. [PMID: 32375178 DOI: 10.1093/rheumatology/keaa142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Alimohammadi N, Koosha F, Rafeian-Kopaei M. Current, New and Future Therapeutic Targets in Inflammatory Bowel Disease: A Systematic Review. Curr Pharm Des 2020;26:2668-75. [PMID: 32250220 DOI: 10.2174/1381612826666200406081920] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
6 Liu W, Wang Z, Liu L, Yang Z, Liu S, Ma Z, Liu Y, Ma Y, Zhang L, Zhang X, Jiang M, Cao X. LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity. Proc Natl Acad Sci U S A 2020;117:23695-706. [PMID: 32907941 DOI: 10.1073/pnas.2003932117] [Cited by in Crossref: 15] [Cited by in F6Publishing: 46] [Article Influence: 7.5] [Reference Citation Analysis]
7 White SJW, Ranson WA, Cho B, Cheung ZB, Ye I, Carrillo O, Kim JS, Cho SK. The Effects of Preoperative Steroid Therapy on Perioperative Morbidity and Mortality After Adult Spinal Deformity Surgery. Spine Deform 2019;7:779-87. [PMID: 31495479 DOI: 10.1016/j.jspd.2018.12.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
8 White SJ, Carrillo O, Cheung ZB, Ranson WA, Cho SK. The Effects of Preoperative Steroid Therapy on Perioperative Complications After Elective Anterior Lumbar Fusion. World Neurosurgery 2019;126:e314-22. [DOI: 10.1016/j.wneu.2019.02.048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Idborg H, Zandian A, Ossipova E, Wigren E, Preger C, Mobarrez F, Checa A, Sohrabian A, Pucholt P, Sandling JK, Fernandes-Cerqueira C, Rönnelid J, Oke V, Grosso G, Kvarnström M, Larsson A, Wheelock CE, Syvänen AC, Rönnblom L, Kultima K, Persson H, Gräslund S, Gunnarsson I, Nilsson P, Svenungsson E, Jakobsson PJ. Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients. Front Immunol 2019;10:1029. [PMID: 31156624 DOI: 10.3389/fimmu.2019.01029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
10 Deng J, Chalhoub NE, Sherwin CM, Li C, Brunner HI. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum 2019;49:251-9. [PMID: 30987856 DOI: 10.1016/j.semarthrit.2019.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Neuman H, Mor H, Bashi T, Givol O, Watad A, Shemer A, Volkov A, Barshack I, Fridkin M, Blank M, Shoenfeld Y, Koren O. Helminth-Based Product and the Microbiome of Mice with Lupus. mSystems 2019;4:e00160-18. [PMID: 30801028 DOI: 10.1128/mSystems.00160-18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
12 Felten R, Scher F, Sibilia J, Chasset F, Arnaud L. Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. Joint Bone Spine 2019;86:429-36. [PMID: 30243784 DOI: 10.1016/j.jbspin.2018.09.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
13 Sanmartí R, Tornero J, Narváez J, Muñoz A, Garmendia E, Ortiz AM, Abad MA, Moya P, Mateo ML, Reina D, Salvatierra-Ossorio J, Rodriguez S, Palmou-Fontana N, Ruibal-Escribano A, Calvo-Alén J. Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review. Reumatol Clin (Engl Ed) 2020;16:222-8. [PMID: 30057295 DOI: 10.1016/j.reuma.2018.06.007] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Ranson WA, White SJW, Cheung ZB, Mikhail C, Ye I, Kim JS, Cho SK. The Effects of Chronic Preoperative Steroid Therapy on Perioperative Complications Following Elective Posterior Lumbar Fusion. Global Spine J 2018;8:834-41. [PMID: 30560036 DOI: 10.1177/2192568218775960] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
15 Ruiz-arruza I, Lozano J, Cabezas-rodriguez I, Medina J, Ugarte A, Erdozain J, Ruiz-irastorza G. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study. Arthritis Care Res 2018;70:582-91. [DOI: 10.1002/acr.23322] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
16 Bartko J, Derhaschnig U, Neels T, Nabozny GH, Harcken C, Leuschner J, De Vries F, Jilma B. Selective glucocorticoid receptor modulation inhibits cytokine responses in a canine model of mild endotoxemia. Pharmacol Res 2017;125:215-23. [PMID: 28923543 DOI: 10.1016/j.phrs.2017.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Stojan G, Petri M. The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years? Curr Treatm Opt Rheumatol 2017;3:164-72. [PMID: 28840094 DOI: 10.1007/s40674-017-0069-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
18 Menezes RR, Godin AM, Rodrigues FF, Coura GME, Melo ISF, Brito AMS, Bertollo CM, Paulino TP, Rachid MA, Machado RR, Coelho MM. Thiamine and riboflavin inhibit production of cytokines and increase the anti-inflammatory activity of a corticosteroid in a chronic model of inflammation induced by complete Freund's adjuvant. Pharmacol Rep 2017;69:1036-43. [PMID: 28958614 DOI: 10.1016/j.pharep.2017.04.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
19 Lu M, Xu W, Gao B, Xiong S. Blunting Autoantigen-induced FOXO3a Protein Phosphorylation and Degradation Is a Novel Pathway of Glucocorticoids for the Treatment of Systemic Lupus Erythematosus. J Biol Chem 2016;291:19900-12. [PMID: 27481940 DOI: 10.1074/jbc.M116.728840] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
20 Moallem E, Koren E, Ulmansky R, Pizov G, Barlev M, Barenholz Y, Naparstek Y. A liposomal steroid nano-drug for treating systemic lupus erythematosus. Lupus 2016;25:1209-16. [DOI: 10.1177/0961203316636468] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
21 Hanly JG, Sayani A, Doucette S, Iczkovitz S, Terres JAR. Treatment pathways in an inception lupus cohort over the first three years. Lupus 2017;26:119-24. [PMID: 27365369 DOI: 10.1177/0961203316655213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
22 Bogaczewicz A, Sobow T, Bogaczewicz J, Bienkowski P, Kowalski J, Wozniacka A. Chloroquine-induced subacute paranoid-like disorder as a complication of dermatological treatment. Int J Dermatol 2016;55:1378-80. [DOI: 10.1111/ijd.13266] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
23 Kasturi S, Sammaritano LR. Corticosteroids in Lupus. Rheumatic Disease Clinics of North America 2016;42:47-62. [DOI: 10.1016/j.rdc.2015.08.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
24 Tsang-A-Sjoe MW, Bultink IE. Systemic lupus erythematosus: review of synthetic drugs. Expert Opin Pharmacother 2015;16:2793-806. [PMID: 26479437 DOI: 10.1517/14656566.2015.1101448] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
25 Selmi C. Autoimmunity in 2013. Clin Rev Allergy Immunol 2014;47:100-9. [PMID: 24819586 DOI: 10.1007/s12016-014-8426-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
26 Bianco A, Muller S. Nanomaterials, Autophagy, and Lupus Disease. ChemMedChem 2016;11:166-74. [PMID: 26194870 DOI: 10.1002/cmdc.201500233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
27 Relle M, Weinmann-Menke J, Scorletti E, Cavagna L, Schwarting A. Genetics and novel aspects of therapies in systemic lupus erythematosus. Autoimmun Rev 2015;14:1005-18. [PMID: 26164648 DOI: 10.1016/j.autrev.2015.07.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
28 Bazsó A, Szappanos Á, Patócs A, Poór G, Shoenfeld Y, Kiss E. The importance of glucocorticoid receptors in systemic lupus erythaematosus. A systematic review. Autoimmunity Reviews 2015;14:349-51. [DOI: 10.1016/j.autrev.2014.12.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
29 Feng Y, Wang C, Cheng S, Wang X, Meng X, Li L, Du J, Liu Q, Guo Y, Meng Y, Cheng B, Ling C. Ginsenoside Rh1 Improves the Effect of Dexamethasone on Autoantibodies Production and Lymphoproliferation in MRL/lpr Mice. Evid Based Complement Alternat Med 2015;2015:727650. [PMID: 25918545 DOI: 10.1155/2015/727650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Wu T, Ye Y, Min SY, Zhu J, Khobahy E, Zhou J, Yan M, Hemachandran S, Pathak S, Zhou XJ, Andreeff M, Mohan C. Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid. Arthritis Rheumatol 2014;66:3129-39. [PMID: 25047252 DOI: 10.1002/art.38782] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
31 van der Goes MC, Jacobs JW, Bijlsma JW. The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects. Arthritis Res Ther 2014;16 Suppl 2:S2. [PMID: 25608693 DOI: 10.1186/ar4686] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 7.3] [Reference Citation Analysis]
32 Steinman L, Shoenfeld Y. From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela. J Autoimmun 2014;54:1-7. [PMID: 25308417 DOI: 10.1016/j.jaut.2014.08.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
33 Liu B, Shu S, Kenny TP, Chang C, Leung PSC. Stem Cell Therapy in Autoimmune Rheumatic Diseases: a Comprehensive Review. Clinic Rev Allerg Immunol 2014;47:244-57. [DOI: 10.1007/s12016-014-8445-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
34 Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus 2014;23:905-12. [PMID: 24795067 DOI: 10.1177/0961203314532562] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
35 Rekvig OP, Van der Vlag J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol 2014;36:301-11. [PMID: 24763531 DOI: 10.1007/s00281-014-0428-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 6.8] [Reference Citation Analysis]
36 Xiao X, Miao Q, Chang C, Gershwin ME, Ma X. Common variable immunodeficiency and autoimmunity--an inconvenient truth. Autoimmun Rev 2014;13:858-64. [PMID: 24747700 DOI: 10.1016/j.autrev.2014.04.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
37 Yu C, Gershwin ME, Chang C. Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun 2014;48-49:10-3. [PMID: 24461385 DOI: 10.1016/j.jaut.2014.01.004] [Cited by in Crossref: 171] [Cited by in F6Publishing: 143] [Article Influence: 21.4] [Reference Citation Analysis]
38 Chang C. Unmet needs in the treatment of autoimmunity: from aspirin to stem cells. Autoimmun Rev 2014;13:331-46. [PMID: 24462645 DOI: 10.1016/j.autrev.2014.01.052] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
39 Ziemer M, Milkova L, Kunz M. Lupus erythematosus. Part II: clinical picture, diagnosis and treatment. J Dtsch Dermatol Ges 2014;12:285-301; quiz 302. [PMID: 24423191 DOI: 10.1111/ddg.12254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Hoekstra M, Frodermann V, van den Aardweg T, van der Sluis RJ, Kuiper J. Leukocytosis and enhanced susceptibility to endotoxemia but not atherosclerosis in adrenalectomized APOE knockout mice. PLoS One 2013;8:e80441. [PMID: 24265824 DOI: 10.1371/journal.pone.0080441] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
41 Zhong LL, Bian ZX, Gu JH, Zhou X, Tian Y, Mao JC, Chen XJ. Chinese Herbal Medicine (Zi Shen Qing) for Mild-to-Moderate Systematic Lupus Erythematosus: A Pilot Prospective, Single-Blinded, Randomized Controlled Study. Evid Based Complement Alternat Med 2013;2013:327245. [PMID: 23737826 DOI: 10.1155/2013/327245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]